Scynexis, Inc. is recalling 17,376 units of Brexafemme (ibrexafungerp) 150 mg tablets due to potential cross-contamination. The ibrexafungerp citrate drug substance may have been contaminated with ezetimibe, which is a non-antibacterial beta-lactam compound. No incidents or injuries have been reported to date. This recall affects 4-count cartons sold at pharmacies throughout the United States.
The presence of a beta-lactam compound like ezetimibe in the medication poses a risk of severe allergic reactions or other health complications for patients with known sensitivities to beta-lactam drugs.
You have 2 options:
Rx Only medication manufactured for Scynexis, Inc.
Carton label Brexafemme Ibrexafungerp tablets 150 mg per tablet
Blister pack label Brexafemme Ibrexafungerp tablets 150 mg per tablet
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · FDA Press Release · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.